Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
Intravenous cyclophosphamide (IVCY) has been used to treat severe lupus nephritis (LN) for many years. Because of the wide variety of manifestations of the condition and the long-term nature of the disease, outcomes vary widely.
To evaluate and compare the immediate and long-term results of IVCY in pediatric onset severe LN and between patients with normal and abnormal initial renal function.
Patients aged <18 years who attended the Department of Pediatrics, Prince of Songkla University, diagnosed with severe LN, and who were given a 36-month IVCY course, were included. Comparison of overall survival between the two groups was assessed using Kaplan–Meier survival curves.
108 patients with a mean age of 12.6 ± 2.7 years were studied, with a mean follow-up time of 5.7 ± 4.3 years. 48 patients completed the IVCY course. 36 patients had abnormal renal function and 72 patients had normal renal function at the start of therapy. Both groups responded well initially to treatment; proteinuria reduced to normal levels after 1 and 2 treatments in the normal and abnormal groups, respectively, while creatinine clearance returned to normal levels after 8 treatments in the abnormal group. Overall survival was not different between the two groups; however, the abnormal renal function group had a higher crude mortality rate than the normal group (13/36 vs 10/72, p value = 0.02). At the time of analysis, some patients who had completed their IVCY course still required other therapy to control their disease activity.
Three years of IVCY treatment provided similar outcomes in both normal and abnormal renal function groups. Immediate outcomes were favorable but long-term remission was not promising.
- Adams A, MacDermott EJ, Lehman TJ (2006) Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs 66:1191–1207 CrossRef
- Niaudet P (2000) Treatment of lupus nephritis in children. Pediatr Nephrol 14:158–166 CrossRef
- Dooley MA, Falk RJ (2007) Human clinical trials in lupus nephritis. Semin Nephrol 27:115–127 CrossRef
- Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228 CrossRef
- Tucker LB, Menon S, Schaller JG et al (1995) Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 34:866–872 CrossRef
- Austin HA, Balow JE (2000) Treatment of lupus nephritis. Semin Nephrol 20:265–276
- Balow JE, Boumpas DT, Austin HA III (2000) New prospects for treatment of lupus nephritis. Semin Nephrol 20:32–39
- Kim YG, Kim HW, Cho YM et al (2008) The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment. Rheumatology (Oxford) 47:311–314 CrossRef
- Dixit MP, Bracamonte E, Dixit N (2004) Intravenous cyclophosphamide–resistant systemic lupus erythematosus in Arizona. Pediatr Nephrol 19:738–743 CrossRef
- Boumpas DT, Austin HA III, Vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745 CrossRef
- Neumann K, Wallace DJ, Azen C et al (1995) Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 25:47–55 CrossRef
- Bansal VK, Beto JA (1997) Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 29:193–199 CrossRef
- Houssiau FA, Vasconcelos C, D’Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131 CrossRef
- Vachvanichsanong P, Dissaneewate P, Winn T (2004) Intravenous cyclophosphamide for lupus nephritis in Thai children. Scand J Rheumatol 33:339–342 CrossRef
- Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277 CrossRef
- R Development Core Team. R. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, Available at: www.R-project.org. [accessed 1 December 2010]
- Mok CC, Ying KY, Tang S et al (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50:2559–2568 CrossRef
- Al Salloum AA (2003) Cyclophosphamide therapy for lupus nephritis: poor renal survival in Arab children. Pediatr Nephrol 18:357–361
- Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136:243–247 CrossRef
- Vachvanichsanong P, Dissaneewate P, McNeil E (2009) Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood-onset lupus nephritis: a 23-year experience in a single centre. Nephrol Dial Transpl 24:2729–2734 CrossRef
- Laoprasopwattana K, Dissaneewate P, Vachvanichsanong P (2009) Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide. Pediatr Nephrol 24:1337–1343 CrossRef
- Mok CC, Ying KY, Ng WL et al (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119:355.e25–355.e33 CrossRef
- Cunha I, Saavedra MJ, Pereira da Silva JA et al (2008) Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus. Acta Reumatol Port 33:69–76
- Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
International Urology and Nephrology
Volume 45, Issue 5 , pp 1301-1308
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Lupus nephritis
- Systemic lupus erythematosus
- Intravenous cyclophosphamide
- Industry Sectors
- Author Affiliations
- 1. Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hat Yai, 90110, Songkla, Thailand
- 2. Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, 90110, Thailand